Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Haleon PLC ( (GB:HLN) ) has provided an announcement.
Haleon plc has executed further purchases of its own ordinary shares as part of the share buyback programme launched in March 2026, acquiring 12,171,987 shares for cancellation across multiple trading venues between 27 April and 1 May. Following these transactions, the company’s registered share capital stands at 8,890,467,595 shares, of which 12,240,797 are held in treasury, leaving 8,878,226,798 shares with voting rights.
The latest tranche of buybacks underscores Haleon’s ongoing capital management strategy, which is likely aimed at enhancing earnings per share and optimizing its balance sheet after its market debut as an independent consumer health group. The updated voting share count also provides investors with a revised reference point for disclosure obligations under U.K. transparency rules and may influence institutional ownership thresholds and index weightings.
The most recent analyst rating on (GB:HLN) stock is a Buy with a £512.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.
Spark’s Take on HLN Stock
According to Spark, TipRanks’ AI Analyst, HLN is a Neutral.
The score is driven primarily by solid financial performance (consistent free cash flow and improving profitability) and a cautiously positive earnings outlook supported by margin gains and cost savings. This is tempered by weaker near-term technical momentum and only moderate valuation support.
To see Spark’s full report on HLN stock, click here.
More about Haleon PLC
Haleon plc is a global consumer health company focused on improving everyday health through over-the-counter products. Its portfolio spans oral health, vitamins, minerals and supplements, pain relief, respiratory, digestive and therapeutic skin health, with brands such as Advil, Centrum, Panadol, Sensodyne, Theraflu and Voltaren reaching more than one billion consumers worldwide.
Average Trading Volume: 22,459,251
Technical Sentiment Signal: Sell
Current Market Cap: £30.55B
For an in-depth examination of HLN stock, go to TipRanks’ Overview page.